Replies to post #234937 on Elite Pharmaceuticals Inc (ELTP)

[namtae]

More BS to hide the truth of whats really going on at Elite

Dont forget, the evidence is clear and decisive, Sequest will receive FDA approval on or before July 14th and...BUY everything under 35!

lmao

[John_Langston]

How is that working out thus far? 97¢ to 40¢ to 15¢. lol

[Drugdoctor]

Nice post - lots of good info in there...

[Don'tDrinkTheKoolAid]

All complete non-sense none of it has come to fruition or will come to fruition. Just a bunch of wishful dreams really. The stock price is speaking volumes. LOL .40 to .14 woo hoo

[littlerhody]

Couch,

Good info- the last paragraph in this post outlines the process for meetings with the FDA. Is the upcoming meeting the first or second meeting? Is it possible that SequestOx can receive approval at this meeting or will additional trials be required. ELTP is a marathon and not a sprint and like you and others I am in for the entire 26 plus miles.
Thanks for your inciteful posts and keep them coming!

[Johnnys1]

Excellent post and due diligence. Thank you.

[Couch]

****SO AFTER reading all of this - one begins to understand the RISK/REWARD scenario. IMO the RISK is rather limited to the REWARD and upside. AGAIN, IMO.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=126901311

AND I wrote this POST PRIOR to ELTP gaining the PATH FORWARD via SequestOX..........the RISK/REWARD scenario just UP with the REWARD side and even lower on the RISK side.

http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=82830&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0

Elite Provides Update On SequestOx™ New Drug Application
NORTHVALE, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the Company met with the U.S. Food and Drug Administration (the "FDA") on December 21, 2016 for an end-of-review meeting to discuss steps that Elite can take to obtain approval of SequestOx™. Based on the FDA response, the Company believes there is a clear path forward to address the issues cited in the July 14th Complete Response Letter ("CRL"). The FDA will provide minutes of the meeting by the end of January and the Company will issue a further update at that time.

SequestOx™ (oxycodone hydrochloride and naltrexone hydrochloride) is Elite's investigational abuse-deterrent opioid candidate for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate. The proposed plan submitted by the Company addresses items cited in the CRL dated July 14, 2016 for the New Drug Application (the "NDA") for SequestOx™.

"We are extremely pleased that there is a path forward to seek FDA approval of SequestOx™," said Nasrat Hakim, President and CEO of Elite. "Based on the guidance received from the agency, Elite will begin to execute the proposed plan immediately."